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Abstract 
Background: Methyl-aminolevulinate photodynamic therapy (MAL-PDT) is a 
successful topical treatment for a number of (pre)cancerous dermatological 
conditions.  In combination, light of the appropriate wavelength, the 
photosensitiser, protoporphyrin IX (PpIX) and tissue oxygen result in the 
production of singlet oxygen and reactive oxygen species inducing cell death.  
This study investigates real-time changes in localised tissue blood oxygen 
saturation and perfusion in conjunction with PpIX fluorescence monitoring for 
the first time during dermatological MAL-PDT.  
Methods: Oxygen saturation, perfusion and PpIX fluorescence were monitored 
non-invasively utilising optical reflectance spectroscopy, laser Doppler perfusion 
imaging and a fluorescence imaging system respectively.  Patients attending for 
standard dermatological MAL-PDT were recruited to this ethically approved 
study and monitored prior to, during and after light irradiation.   
Results: Significant reductions in mean blood oxygen saturation (P<0.005) and 
PpIX fluorescence (P<0.001) were observed within the first minute of irradiation 
(4.75 Jcm-2), whilst in contrast perfusion was observed to significantly increase 
(P<0.01) during treatment.  The changes in oxygen saturation and PpIX 
fluorescence were positively correlated during the initial phase of treatment 
(r2=0.766).   
Conclusion: Rapid reductions in the localised blood oxygen saturation have 
been observed to occur clinically for the first time within the initial minutes of 
light irradiation and positively correlate with the concurrent PpIX 
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photobleaching.  Furthermore perfusion increases suggesting that the 
microvasculature compensates for the PDT induced oxygen depletion.   
Keywords: Dermatology; Fluorescence diagnosis (FD); Methyl-aminolevulinate 
(MAL); Oxygen saturation, Photodynamic therapy (PDT) 
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Introduction  
Photodynamic therapy (PDT) utilises a photosensitiser, light of an appropriate 
wavelength and tissue oxygen to selectively ablate (pre)malignant tissue 
(Henderson & Dougherty, 1992; Peng et al, 1997).  These three critical 
components, when available in a plentiful supply, result in the production of 
singlet oxygen and other reactive oxygen species (ROS) which lead to cellular 
damage and ultimately cell death via apoptotic and necrotic pathways 1.   The 
absence of any one of the three components prevents the formation of ROS 
and thus tissue ablation 2.   
Methyl-aminolevulinate (MAL) PDT employs a topical prodrug to accumulate the 
endogenous photosensitiser, protoporphyrin IX (PpIX), preferentially within 
tumour cells and this treatment has found a particular niche in the treatment of 
(pre)cancerous dermatological indications including actinic keratosis (AK), 
Bowen’s disease (BD) and superficial basal cell carcinoma (sBCC) 3,4.  PpIX 
(the penultimate molecule in the haem biosynthesis pathway) selectively 
accumulates within (pre)cancerous lesions/cells due to their disrupted stratum 
corneum, upregulation of the haem biosynthesis pathway and alterations in the 
expression of the porphobilinogen deaminase and ferrochelatase enzymes 
within the pathway 4.   
Activation of the accumulated PpIX with red light (635 nm) results in the 
localised production of ROS and singlet oxygen, providing sufficient tissue 
oxygen is present 4.  The critical importance of a plentiful oxygen supply during 
PDT has long been recognised 5-7 with studies demonstrating that tumours with 
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pre-existing hypoxia or tumours that develop hypoxia during PDT respond with 
limited efficacy to PDT 8-10.       
Monitoring tissue oxygenation during and after PDT therefore has the potential 
to enhance our understanding of the basic physiological mechanisms involved 
during light irradiation.  Additionally, monitoring oxygen during PDT may enable 
the efficacy of the PDT treatment to be predicted as the cytotoxic effect of PDT 
is partly dependent on the availability of oxygen 11,12.   
Many studies have utilised a variety of different techniques to monitor oxygen 
saturation (or the partial pressure of oxygen, pO2) in the tissue before, during 
and after the light irradiation phase of PDT.  All but one of these studies have 
been in animal models. These studies have highlighted several general 
conclusions:  Significant changes in oxygenation were observed to occur during 
and after PDT, with markedly different responses noted for the different 
photosensitisers employed 8,9,13-15.  A rapid decline in pO2 immediately on the 
initiation of light treatment was also noted in a number of studies 10,14,16,17.  This 
rapid depletion in oxygen is attributed to the photochemical consumption of 
oxygen and damage to the microvasculature reducing the capacity of the 
circulation to replenish the tissue with oxygen 13,18.   
A steep decline in pO2 was noted immediately after commencing light treatment 
in mouse and rat models treated with PpIX mediated-PDT where 
aminolaevulinic acid (ALA) was utilised as the topical pro-drug 14,19, although 
other studies have demonstrated large increases in tumour oxygenation during 
ALA-PDT 15.  The only clinical observations with ALA-PDT monitored eight 
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nodular BCC lesions, indicating 5-20% reductions in haemoglobin saturation, 
which were highly dependent on the fibre position 20.  To date we are unaware 
of any clinical MAL-PDT studies which have considered pO2. 
Furthermore insights into the physiological changes induced by PDT can be 
gained by monitoring the alteration in perfusion.  To date perfusion alterations 
during PpIX mediated PDT have not demonstrated unified alterations with 
fluence and fluence rate influencing the perfusion alterations.  Increased 
perfusion within BCC lesions was observed following ALA-PDT in one study 21, 
although alternative clinical studies have indicated no immediate perfusion 
alterations during either ALA or MAL-PDT and significant reductions in 
perfusion during high fluence ALA-PDT (100 Jcm-2) have been observed in pre-
clinical 22 and clinical studies 23.  To date we are unaware of any clinical MAL-
PDT studies which have employed a standardised irradiation protocol.  
This investigation therefore monitored, for the first time, mean blood oxygen 
saturation, perfusion and PpIX fluorescence within three histologically distinct 
dermatological lesion types (AK, BD and sBCC) during clinical MAL-PDT 
treatment.  Changes in the localised tissue blood oxygen concentration and 
perfusion were monitored during treatment and common trends between the 
three distinct lesion types treated were identified.  The relationship between 
changes in tissue oxygen saturation and changes in PpIX fluorescence during 
light irradiation were also considered.               
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Materials and Methods 
Clinical data  
Patients attending the PDT service at the Dermatology Department, Royal 
Cornwall Hospital, Truro, UK were provided with verbal and written information 
about this ethically approved non-invasive monitoring study (Plymouth and 
Cornwall Research Ethics Committee) prior to providing written consent.  Fifty-
five patients (20 males and 35 females; mean age 70 +/- 10 years) were 
recruited with a range of licensed indications (24 AK, 14 BD and 17 sBCC) 
localised at both acral and non-acral sites (22 acral and 33 non-acral).  The 
average surface area of the lesion was 35 mm2 +/- 9 mm2.  BD and sBCC were 
biopsy proven prior to treatment, whilst AK lesions were referred at the 
Consultant Dermatologist’s discretion.  The clinical nurse specialists treated all 
lesions as per the current National Institute of Clinical Excellence (NICE, 2006) 
guidelines for MAL-PDT.  Following appropriate lesion preparation, MAL was 
applied for three hours at approximately 1 mm thickness with a 5 mm border 
around the lesion.  After the three hour application time any excess MAL was 
removed and the area was then irradiated with red light (Aktilite®, Galderma, 
UK; 635 nm; 37 Jcm-2; 80 mWcm-2).  
Fluorescence imaging:  The lesions were monitored with a previously validated 
non-invasive fluorescence imaging system (Dyaderm, Biocam, Germany) 
following the previously derived standard operating procedure to ensure 
reproducible images were acquired 24.  Each lesion was imaged at four distinct 
time points during treatment; (1) prior to the application of MAL, (2) after the 
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three hour application of MAL, (3) during light irradiation either after 1 minute 
(4.75 Jcm-2, 10 patients - 5 males and 5 females, mean age 75 +/- 4 years; 3 
AK, 3 BD and 4 sBCC) or at the half way stage (18.5 Jcm-2) during treatment 
(45 patients (based on previous studies where statistical significance was 
demonstrated at 90 % power at P<0.001 25 - 15 males and 30 females; mean 
age 69 +/- 11 years; 12 AK, 7 BD and 6 sBCC)) and (4) following the 
completion of light treatment (37 Jcm-2).  The acquisition of each image took a 
maximum of 60 seconds.    
Oxygen saturation monitoring:  In addition to the fluorescence imaging, the 
mean blood oxygen saturation (SmbO2 - percentage of haemoglobin carrying 
oxygen, averaged across all the microvessels in the volume of skin studied) of 
the tissue was monitored prior to, during (10 patients (5 males and 5 females, 
mean age 75 +/- 4 years; 3 AK, 3 BD and 4 sBCC ) at 4.75 Jcm-2 and 25 
patients (8 males and 17 females; mean age 69 +/- 11 years; 12 AK, 7 BD and 
6 sBCC) at 18.5 Jcm-2) and at the end of light irradiation.  The SmbO2 was 
calculated by spectroscopic quantification of the two chromophores 
oxyhaemoglobin (HbO2) and deoxyhaemoglobin (Hb), using a previously 
validated ‘in house’ optical reflectance spectroscopy (ORS) instrumentation 
(School of Physics, University of Exeter, UK) 26.   Light from a stabilised quartz 
tungsten halogen white light source was delivered to the skin via a fibre optic 
probe.  Backscattered light was collected by six concentric fibres set 250 µm 
from the source enabling depths of 200 µm to be monitored which approximated 
to the depth of the lesions being investigated 27.  Backscattered spectra ranging 
from 470-1120 nm were recorded in 0.05 seconds through a grating 
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spectrometer and charge-coupled device camera and processed with custom 
written Windows-based software.  The concentrations of HbO2 and Hb were 
derived from the modified Beer-Lambert law using a four component multi-linear 
regression algorithm on a narrow spectral range (500-600 nm) where a linear 
relationship between scattering of blood and wavelength was assumed.  To 
obtain spectra from the blood volume alone, an initial reference spectrum from 
the surrounding interstitium of the lesion was acquired by applying sufficient 
pressure on the probe to occlude the microvessels 26,28. The mean blood 
oxygen saturation was derived from the measured concentrations of HbO2 and 
Hb and defined as oxygen saturation (%) = [HbO2]x100/([HbO2]+[Hb]). This 
oxygen saturation is the mean blood oxygen saturation across the arterioles 
capillaries and venules in the cutaneous microcirculation under investigation.  
For each time point the oxygen saturation within the tissue was monitored for 60 
seconds. Consistent probe placement within the lesion limited the effect of the 
heterogeneous microvasculature. Reproducibility studies of probe placement on 
normal skin produced a coefficient of variance (CV) of less than 7% (data not 
shown).  
Laser Doppler Perfusion Imaging:  The skin microcirculation was studied with a 
well established technique, laser Doppler fluximetry, which has previously been 
employed to monitor dermatological ALA-PDT 21,29.  A Periscan PIM II perfusion 
imager (Perimed, Sweden) instrument was utilised to monitor perfusion within 
normal skin and the (pre)cancerous lesion treated with MAL-PDT.  A single 
wavelength of low power (1 mW) laser light (670 nm) was directed onto the 
surface of the skin and the entire lesion scanned.  Light backscattered from the 
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tissue was collected by the photodetector, light scattered from moving objects 
(e.g. red blood cells) underwent frequency changes, or Doppler shift, whereas 
light backscattered from stationary objects remained unaltered.  The magnitude 
and frequency distribution of the Doppler shift is a measure of the number and 
velocity of blood cells in the volume of tissue under investigation.  The perfusion 
in the skin is quantified by the term flux (in arbitrary units) which is the product 
of the mean moving red blood cell velocity and the number of moving red blood 
cells. Following the scan, perfusion was monitored at a number of discrete 
points using the LDPIWin software (Perimed, Sweden) and the average 
perfusion of the lesion and normal skin was calculated, reducing the signal 
noise and the effects of spatial variations in the tissue.  Patients (20 patients – 7 
males and 13 females; average age 69 years +/- 8.3 years; 9 AK, 4 BD and 7 
sBCC) were monitored prior to light treatment, during light irradiation (at the half 
way stage) and following the completion of treatment for a maximum of 90 
seconds.  To ensure the continuity of the system a calibration box was scanned 
before and after every patient and no significant variation was observed 
(P=0.526; data not shown).   
 
Temperature:  Skin temperature was monitored with a digital thermometer 
(Fluke Ltd, UK) during the acquisition of oxygen saturation and perfusion 
measurements. 
 
Data analysis 
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Fluorescence images (BMP – to ensure no data was lost by condensing the 
image) from patients were exported into NIH ImageJ software 
(http://rsb.info.nih.gov/ij/) and analyzed from the same point within the lesion.  
The normality of the data was analysed with the Kolmogorov-Smirnov test.  
Normally distributed data were either analysed with the unpaired t-test or 
ANOVA analysis for between group comparisons or the paired t-test or 
repeated measures ANOVA for intra patient data.   
Least squares regression analysis and Spearman Rank analysis was utilised to 
determine the relationship between changes in oxygen saturation and PpIX 
concentration during treatment.   
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Results  
Oxygen saturation 
In the twenty-five patients whose mean blood oxygen saturation was measured 
after the delivery of 0, 18.5 and 37 Jcm-2 of light, a significant reduction 
(P<0.005) in oxygen saturation during light treatment was observed.  Oxygen 
saturation was significantly lower (P<0.005) both during and at the end of 
irradiation compared to the pre-irradiation value (Figure 1).  No statistically 
significant difference was noted between the final oxygen saturation value and 
that recorded at the half-way stage (P=0.165).     
A significant decrease (P<0.005) in lesion oxygen saturation was also observed 
for the ten patients monitored after 0, 4.75 and 37 Jcm-2 of light delivery (Figure 
2).  The two latter measurements were found to be significantly lower (P<0.005) 
than the initial oxygen saturation recorded (Figure 2).  In contrast the oxygen 
saturation recorded at 4.75 and 37 Jcm-2 were noted to be similar (P=0.314; 
Figure 2).  
Significant reductions (P<0.005) in oxygen saturation during light irradiation 
were noted irrespective of the histological lesion type, anatomical location of the 
lesion (8 acral versus 17 non-acral skin) and patient gender (8 males and 17 
females).   
The initial oxygen saturation values recorded within these lesions were in the 
same range as previously determined oxygen saturation values for normal skin 
in identical anatomical locations (data not shown) 28,30.   
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The average decrease in oxygen saturation within the first minute (4.75 Jcm-2; 
10 patients) was noted to be similar (P=0.845, Figure 3) to the average 
decrease in oxygen saturation after the first half of light treatment (18.5 Jcm-2; 
25 patients) although significantly more data would be required to demonstrate 
whether the changes observed within the first minute were similar to the 
changes in oxygen saturation in the first half of light irradiation.   
Perfusion 
Perfusion within lesions was noted to be significantly greater (P<0.01; Figure 1) 
than perfusion within distal normal skin both before and after light irradiation.  
During the first half of light irradiation perfusion within the lesion increased 
significantly (P<0.001) and perfusion then remained significantly greater at the 
cessation of treatment (P<0.01).  In contrast perfusion at the half-way stage 
was similar to the perfusion at the cessation of treatment (P=0.160).  The 
perfusion within distal normal skin remained unaltered (P=0.42).   
The change in perfusion during the first half of light treatment was significantly 
greater (P<0.01) than the changes during the second half of the irradiation.  
Temperature 
The localised skin temperature was observed to fluctuate during MAL-PDT with 
25% of patients undergoing significant increases in temperature (up to +2°C, 
P<0.05, data not shown).  However when the raw data was analysed as a 
whole no significant difference was noted in skin temperature during irradiation 
(P=0.18; Figure 1). 
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Fluorescence  
During light irradiation PpIX fluorescence was observed to significantly 
decrease (P<0.001; Figure 1).  The decrease in PpIX fluorescence during light 
irradiation was significantly greater during the first half of irradiation (P<0.001) 
than during the second half of treatment, however during the second half of the 
irradiation period the decrease in PpIX fluorescence still remained statistically 
significant (P<0.01).  A weak positive correlation was noted between total PpIX 
fluorescence prior to irradiation and PpIX photobleaching (r2=0.55, P<0.01); as 
previously demonstrated 31).         
Potential correlations between the oxygen saturation and PpIX fluorescence 
data were investigated.  No correlations were observed between the initial 
oxygen saturation within the tissue and the level of PpIX photobleaching that 
occurred during irradiation (r2=0.1, P=0.335; data not shown) and the total 
change in oxygen saturation and the total level of PpIX photobleaching during 
light irradiation (r2=0.122, P=0.169; data not shown).  Stronger correlations 
were observed between the changes in oxygen and PpIX photobleaching 
observed during the first half (r2=0.281, P<0.05; Figure 4a) and the second half 
of irradiation (r2=0.312, P<0.05; Figure 4b) respectively.  The strongest 
correlation was observed between changes in oxygen saturation and 
fluorescence recorded at the end of the first minute of irradiation (r2=0.766, 
P<0.001; Figure 4c).  These relationships were confirmed with the Spearman 
Rank analysis.         
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Discussion 
This investigation measured for the first time the changes in oxygen saturation 
and perfusion at various stages during real-time clinical dermatological MAL-
PDT in a range of licensed indications.  The oxygen saturation within lesions 
was monitored prior to the application of light, after the delivery of either 4.75 
Jcm-2 or 18.5 Jcm-2 light and after the completion of irradiation (37 Jcm-2).  A 
wide variety of responses were noted in different lesions, but the general trend 
observed demonstrated significant reductions in the localised mean blood 
oxygen saturation after the delivery of 18.5 Jcm-2 (Figure 1) and 4.75 Jcm-2 
(Figure 2) of light respectively.  Furthermore the change in oxygen saturation 
observed during the first minute of irradiation was similar to the decrease 
observed in the first half of irradiation (Figure 3).  Significantly more patients 
(over 1000 in each group) would be required to determine if this was a true 
result.  The significant reduction in oxygen saturation was observed during light 
irradiation irrespective of the histological lesion type receiving the MAL-PDT 
treatment, patient gender and lesion location.  Perfusion was also observed to 
significantly alter during treatment with a significant increase in perfusion 
occurring after the onset of irradiation (Figure 1).    
These data provide evidence in man that the effects are similar to those 
previously observed in animals, that is that rapid reductions in the pO2 are 
observed immediately after the initiation of light treatment during PDT 14,17,20,32.  
Figure 2 suggests that the pO2 is significantly depleted within the initial 4.75 
Jcm-2 of light with this form of PDT and then remains at a similar level for the 
remainder of treatment.  This suggests that it is the very early stages of 
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irradiation where the maximal photochemical reactions take place, as previously 
suggested by our PpIX photobleaching study 33.  The reduction in oxygen 
saturation during MAL-PDT is proposed to occur primarily as a result of oxygen 
consumption during the photochemical reactions within cells and to a lesser 
extent, damage to the localised microvasculature may also be involved 13.  
Mean blood oxygen saturation can only provide a measure of the oxygen 
content of the blood in the lesion during irradiation and is not a direct measure 
of tissue oxygenation.  A fall in mean blood oxygen saturation can be induced 
by a decrease in arterial inflow as well as an increase in oxygen consumption 34.  
However, when considered in conjunction with the perfusion data presented 
here, which demonstrated the vasodilatory effect of irradiation it is reasonable to 
attribute this fall in oxygen saturation to an increase in oxygen consumption 
during light irradiation.     
Several studies have investigated perfusion alterations following light irradiation 
during ALA-PDT.  Increased perfusion following light irradiation (as observed 
here in Figure1) was previously noted following the light irradiation stage of 
ALA-PDT treatment of BCC (where a light dose of 60 Jcm-2 was delivered at 
100 mWcm-2) 21 and during PDT with other photosensitisers in animal models 
35,36.  However, another study indicated no significant perfusion alterations 
within 18 BCC lesions pre and post ALA-PDT treatment although this study 
utilised a wide range of fluence rates (20-300 mWcm-2) and total light dose 
delivered (30-100 Jcm-2) and did not investigate the effect of these parameters 
on perfusion 29.  In contrast our study utilised a standardised irradiation protocol 
(37 Jcm-2, 80 mWcm-2), ensuring a more robust investigation of perfusion 
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alterations during MAL-PDT treatment.  Furthermore this study highlighted the 
importance of monitoring during light irradiation to ensure a more complete 
insight into the physiological changes of PDT treatment; one BCC within this 
study underwent no significant difference in perfusion pre and post irradiation, 
but significant changes were observed at the half way stage.  Our findings have 
suggested that perfusion does not solely increase or decrease during MAL-
PDT, rather perfusion initially increases before beginning to decrease, this 
corresponds with previous research suggesting that the concept of 
unidirectional perfusion changes during PDT was misconceived 8.     
 The initial lesional mean blood oxygen saturation recorded was compared with 
previously determined mean values for normal skin in an identical location to 
the lesion and was demonstrated to fall within a similar range.  This indicates 
that despite the disorganised microvasculature and the greater percentage of 
the tissue occupied by blood vessels in the (pre)cancerous lesions monitored 37-
39, the levels of oxygen within lesional and normal microvasculature are similar.  
This suggests a limited hypoxic environment exists within these lesion types, 
potentially enhancing the efficacy of MAL-PDT.   
The changes in PpIX fluorescence were monitored for the first time during MAL-
PDT in conjunction with the ORS data utilising a well established, validated, 
non-invasive fluorescence imaging technique 24.  Figure 1 demonstrates that 
both PpIX photobleaching and oxygen consumption were greater in the first half 
of light treatment when compared to the latter stages of treatment, with 
significant decreases occurring in both the PpIX level and oxygen saturation 
during the first half of treatment.  The significant decrease in PpIX fluorescence 
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is attributed to the destruction of ground state PpIX by singlet oxygen forming 
the photoproduct, photoprotoporphyrin 1,4.  In contrast to oxygen saturation, 
PpIX fluorescence continued to significantly decrease in the second half of light 
treatment (Figure 1) and this may have been via an oxygen independent 
mechanism.       
Intricate relationships have previously been demonstrated between the oxygen 
concentration and PpIX photobleaching in tumour tissue 40.  The relationships 
between oxygen saturation and PpIX fluorescence during MAL-PDT were 
therefore investigated further.  These data suggested a positive correlation 
between the change in PpIX fluorescence and changes in oxygen saturation 
within the first minute of light irradiation (Figure 4c), although this relationship 
requires confirmation and further investigation in a much larger patient cohort.  
Weaker correlations were observed for the changes in PpIX fluorescence and 
oxygen saturation during the first and second half of light irradiation and total 
changes in oxygen saturation and PpIX fluorescence.  The initial oxygen 
saturation of the lesion did not significantly relate to the level of PpIX 
photobleaching either. The relationships between oxygen saturation and PpIX 
fluorescence were also investigated with the Spearman rank correlation and the 
same conclusions were reached, indicating that despite some outliers the data 
were not significantly influenced by these. 
When considered concurrently, the oxygen saturation data, perfusion data and 
PpIX fluorescence changes suggest that on the initiation of light irradiation, 
singlet oxygen/other ROS are rapidly produced via photochemical reactions.  
Hence the pool of available oxygen and ground state PpIX are reduced, via 
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photochemical consumption and singlet oxygen destruction respectively.  The 
rapid oxygen consumption would result in significant reductions in the partial 
pressure of oxygen and therefore potentially the development of a hypoxic 
environment.  This may initiate hypoxia induced vasodilation leading initially to 
increased perfusion as observed to replenish the depleted oxygen supply.  
These data also demonstrate that the oxygen saturation remains low for the 
remainder of treatment, therefore suggesting that the increased perfusion either 
does not significantly replenish the partial pressure of oxygen in the tissue or it 
continues to be consumed by photochemical reactions as the light delivery is 
continued.  It can be concluded however that in the latter stages of treatment 
oxygen consumption is reduced as no significant alterations in this parameter 
were observed at the monitoring points investigated during the second half of 
treatment.  This probably occurs as a result of the significant reduction in PpIX 
availability (due to its photochemical destruction/photobleaching).  As a result 
the perfusion in the tissue being treated may potentially decrease from this point 
onwards.   
The rate of photobleaching is thought to be dependent on the light fluence 
(maintained in this study at 37 Jcm-2), the photosensitiser concentration prior to 
light irradiation (r2=0.55, P<0.01; data not shown) and the pO2 within the tissues 
under investigation 40.  Whilst only relatively weak correlations were observed 
between changes in PpIX fluorescence and oxygen saturation during light 
irradiation this can perhaps be explained by the phased photobleaching that is 
observed during light treatment.  PpIX photobleaching has been demonstrated 
to follow a double exponential decay pre-clinically 41 and recently we have 
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observed a similar relationship clinically during MAL-PDT 33.  The greatest 
correlation existed in the initial minute of light irradiation, which appears to be 
when the majority of oxygen is consumed (in fact changes in tissue oxygen 
saturation within the first minute (4.75 Jcm-2, 10 patients) were not dissimilar to 
the changes that occurred in the whole first half (18.5 Jcm-2, 25 patients) of light 
irradiation), suggesting that the majority of PpIX should be photobleached in the 
early stages of light irradiation (as observed).  The weaker correlations 
observed between PpIX photobleaching and oxygen saturation for the first half, 
second half and total light dose could be explained by oxygen-independent 
photobleaching occurring when the local environment is more hypoxic 41 or an 
increase in arterial inflow due to the vasodilatory effect of irradiation.  
Furthermore our clinical data demonstrated significant interpatient variations as 
a result of numerous external factors, which may potentially alter the capacity 
for photochemical reactions and therefore the relationship between PpIX 
photobleaching and oxygen saturation.   
Monitoring the oxygen saturation of lesions at more time points during light 
irradiation would have been preferable however this study aimed to monitor 
standard clinical treatments without significant intervention. Due to the problems 
of cross-talk with PDT irradiating at 635 nm and laser Doppler perfusion 
imaging 670 nm,  acquisition of measurements required the PDT light source to 
be off and was therefore limited to three occasions, with only one reading 
acquired during the light irradiation procedure.  It is important to note that for 
more accurate monitoring of PpIX photobleaching, oxygen saturation and 
perfusion during light irradiation in the clinical setting a technique enabling 
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continuous monitoring throughout treatment needs to be developed such as has 
been employed with other photosensitisers pre-clinically 42.  Until such time as a 
technique is developed the temporary pausing of the light irradiation protocol for 
a short time (maximum of three minutes within this study) remains the only way 
of gaining an insight into clinical PpIX photobleaching kinetics.  By pausing the 
light a fractionated protocol was employed with a short dark phase, which has 
previously noted to enhance the level of cellular damage/death during ALA-PDT 
14.  Whilst pausing the light to monitor during treatment may not be ideal, the 
photobleaching of PpIX appeared to respond as previously demonstrated in 
pre-clinical models.  This observation increased our confidence in the validity of 
the data despite having to temporarily pause the light delivery.   
Furthermore it would have been preferential to monitor both the oxygen 
saturation and perfusion within all of the patients.  However with clinical time 
constraints this was not feasible and therefore this study was limited by the 
number of patients in each group.  We have demonstrated however that both 
the ORS and LDPI devices can be successfully utilised in a standard clinical 
setting to aid dermatological MAL-PDT investigation/monitoring.  Future work 
should involve the monitoring of a larger number of patients, to confirm the 
observations within this cohort of patients and to extend the study to investigate 
conclusively whether lesion type and lesion location alters changes in oxygen 
saturation and perfusion.  However it should be noted that the results recorded 
here, fit both with our previous work 14,31 and the work of other groups in animal 
models 15,17,23, increasing our confidence in the data despite limited numbers.     
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The different techniques employed within this study probe slightly different 
depths of the skin, which need to be considered in conjunction with our findings.  
Both the fluorescence images and the ORS provide detailed information at the 
epidermis and dermal-epidermal interface respectively.  The LDPI however, 
utilises a longer wavelength of light and therefore probes the skin at deeper 
depths investigating the flow of the superficial plexus within the dermis.  Whilst it 
would be preferable to use techniques that all investigate the same depth this is 
not currently possible with the technology available.  The deeper depth of the 
LDPI may explain why limited correlations were observed between changes in 
perfusion and changes in fluorescence during treatment.   
The heterogeneity of the microvasculature may reduce the reliability of the data 
as only one area within the lesion was monitored.  However our data showed 
that within a lesion oxygenation varied by only 10% and our techniques of 
reproducible probe placement ensured the same region of microvasculature 
was monitored.  There remains the possibility that the values obtained may not 
truly reflect the overall actual oxygen saturation of the lesion, as previous probe 
placement at different sites within the lesion was observed to significantly alter 
the oxygen saturation 20.  However, in light of the consistent trends observed 
when these data were analysed by fluence delivered, lesion type, lesion 
location and patient gender, we consider these observations to be robust and 
the trends valid. 
Overall these findings demonstrated for the first time a rapid decline in oxygen 
saturation occurring during dermatological MAL-PDT following the initiation of 
irradiation and this finding is related to the PpIX photobleaching that is also 
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observed to occur over this time period.  Furthermore this study demonstrated 
an increase in perfusion within lesions during light irradiation, which suggests 
that as oxygen is consumed perfusion increases to replenish depleted tissue 
oxygen stores.  These findings suggest that treatment enhancement could 
investigate improving the oxygen saturation of the tissue either prior to or 
following the initial minute of light irradiation to increase ROS production and 
ultimately treatment efficacy.        
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Figure legends 
Figure 1: Graphical representation of the relative oxygen saturation (n=25), 
PpIX fluorescence (n=45), perfusion (n=20) and temperature (n=45) as a 
function of the light dose delivered.  The error bars represent the standard 
deviation of data and ∆ and ** represents statistical significance at P<0.005 and 
P<0.001 respectively from the pre-irradiation value. * represents significance at 
the P<0.01 level between the post-irradiation value and the value at the half 
way point of irradiation.  
Figure 2: Bar chart representing the oxygen saturation as a function of the light 
dose delivered for the ten patients monitored pre-light application, after 1 minute 
and immediately after the completion of treatment (n=10).  The error bars 
represent the standard deviation and ∆ represents statistical significance at 
P<0.005 from the pre-irradiation value. 
Figure 3: Bar chart representing the mean change in oxygen saturation during 
the first minute (4.75 Jcm-2) and the first half of light treatment (18.5 Jcm-2).  The 
error bars represent the standard deviation of the data.    
Figure 4: Linear regression graphs of the change in oxygen saturation and PpIX 
fluorescence that occurred A) during the first half of irradiation (n=25), B) during 
the second half of irradiation (n=25) and C) during the first minute of irradiation 
(n=10).  The linear regression coefficient is noted.   
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